Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02776813 · ClinicalTrials.gov registry record · Phase 1
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
A Phase 1 study, sponsored by Cogent Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02776813: Completed Phase 1 study, sponsored by Cogent Biosciences.
NCT02776813 is a Phase 1 study that has completed, run by Cogent Biosciences. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02776813, a Phase 1 study, has completed, sponsored by Cogent Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in subjects with refractory or relapsed CD20+ B-cell lymphoma.
Interventions
- BIOLOGICAL rituximab
- BIOLOGICAL ACTR087
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-08 |
| Est. Completion | 2020-02-12 |
| Phase | Phase 1 |
What the finished NCT02776813 record still lists
NCT02776813 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 2 interventions - of which rituximab is the first listed.
NCT02776813 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02776813 about?
NCT02776813 is a clinical study titled "Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma". This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in subjects with refractory or relapsed CD20+ B-cell lymphoma.
What is the current status of trial NCT02776813?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2016-08. Estimated completion is 2020-02-12.
What interventions are being tested in trial NCT02776813?
The interventions under investigation include: rituximab (BIOLOGICAL), ACTR087 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02776813?
This trial is sponsored by Cogent Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02776813's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia